|Videos|November 18, 2019
Imad Najm, MD: Impact of Wearable Technology in Epilepsy
Author(s)Imad Michel Najm, MD
The director of the Epilepsy Center at Cleveland Clinic reviewed the role that wearable technology can play in detecting seizures in patients with epilepsy.
Advertisement
“It may give some benefit to the patient, their family, their loved ones to at least give them at least a warning that this patient may be having a seizure or may have had a seizure.”
Wearable technology has continued to make inroads for detecting epileptic seizures, with one device currently FDA-approved. The devices can serve as warning systems for patients and caregivers, as well as a way for providers to track seizure trends over time. In an interview with NeurologyLive, Imad Najm, MD, the director of the Epilepsy Center at Cleveland Clinic, detailed the important role that wearable technology can play in detecting seizures in patients with epilepsy.
While wearable technology has made strides, there are still shortcomings in the sensitivity of what it can and cannot detect that need to be improved upon. On one hand, patients whose seizures go unnoticed or underreported can be undertreated, and in the case of hypersensitivity, some movements may be wrongly flagged as seizure activity.If recorded incorrectly, it could cause unnecessary mobilization of emergency services.
In the interview, Najm detailed the evolution of wearable devices and their ultimate potential for improving epilepsy care.
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Advertisement
Related Articles
- NeurologyLive® Friday 5 — September 12, 2025
September 12th 2025
- Expanding the Alzheimer Drug Development Pipeline
September 12th 2025
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive
1
MDA and PPMD Release Consensus Guidelines for Safe and Equitable Use of Gene Therapy in Duchenne
2
Expanding the Alzheimer Drug Development Pipeline
3
DORAs Carry Lower Real-World Abuse, New Phase 3 Argus Data, RAP-219 Meets Primary End Point
4
NeurologyLive® Friday 5 — September 12, 2025
5